# A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers

> **NCT05238207** · PHASE1 · TERMINATED · sponsor: **Bond Biosciences** · enrollment: 24 (actual)

## Conditions studied

- Hereditary Hemochromatosis

## Interventions

- **DRUG:** BBI-001
- **DIETARY_SUPPLEMENT:** Original Fibre Metamucil

## Key facts

- **NCT ID:** NCT05238207
- **Lead sponsor:** Bond Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-28
- **Primary completion:** 2023-05-04
- **Final completion:** 2023-05-04
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Only Part A (single dosing) was conducted due to business considerations
- **Last updated:** 2023-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238207, "A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05238207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*